Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EYPT vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–4 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: EYPT 2 – 3 CAPR (1 Tie) Matrix Metrics: EYPT 4 – 5 CAPR

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over EyePoint Pharmaceuticals, Inc. (EYPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). EYPT carries a Unified Composite Score of 43.5/100 (HOLD) at $0.30 (6.2x Forward P/E, -11369.3% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EYPT currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -11369.3% operating margin) and revenue trajectory (-7.9% vs. -90.5% YoY).
  • Technical & Structure Timing Caution: EYPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 17.6); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EYPT vs CAPR
EYPT NASDAQ
EyePoint Pharmaceuticals, Inc. Common Stock
Laboratory Analytical Instruments
$0.30
-3.14% 1D
Market Cap $26.8M
TTM Revenue $2.8M
Forward P/E 6.2x
Beta / 30D Vol 1.43β · 104% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 72.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -54.6%), weak momentum, RSI 18
RSI-14: 17.6 · SMA20: $0.37 · SMA50: $2.24
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (EYPT 2 – 3 CAPR)

Columns: Metric · EYPT · CAPR
1. Valuation Multiples EYPT
Forward P/E 6.2x 78.7x
Trailing P/E 6.2x 78.7x
PEG Ratio N/M 0.38x
EV / Revenue N/M 57.8x
2. Growth & Scale CAPR
Revenue Growth (YoY) -90.5% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.8M $11M
Market Cap $26.8M $595.4M
3. Profitability & Quality CAPR
Gross Margin N/A N/A
Operating Margin -11369.3% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -148.7% -100.5%
4. Balance Sheet & Cash Flow EYPT
Cash Generation (TTM) -$314M EBITDA -$146M
Cash Flow Margin N/A N/A
Net Cash / Leverage $91M Net Cash $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 241.0% (47th %ile) 637.1% (89th %ile)
Put/Call OI Skew 0.16x (Call-Skewed) 1.57x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EYPT (4) vs CAPR (5)
Institutional Metric EYPT CAPR Criterion Row Edge
Market Capitalization
Scale
$26.8M $595.4M Larger Scale CAPR
Trailing P/E Ratio
Valuation
6.2x 78.7x Lower Multiple EYPT
Forward P/E Ratio
Valuation
6.2x 78.7x Lower Multiple EYPT
Revenue Growth (YoY)
Growth
-90.5% -7.9% Higher Growth CAPR
Operating Margin (TTM)
Profitability
-11369.3% 0.0% Higher Margin CAPR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-148.7% -100.5% Higher ROE CAPR
52-Week Range Position
Momentum
0% ($0–$19) 15% ($3–$40) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
1.43β · 104% Vol 1.52β · 152% Vol Lower Realized Risk EYPT
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite EYPT
Trailing 12M Revenue (USD)
Operating Scale
$2.8M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$314M EBITDA ($91M Net Cash) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +116.32 pp
EYPT: -90.09% · CAPR: +26.23%
3M Horizon CAPR +114.21 pp
EYPT: -94.58% · CAPR: +19.63%
6M Horizon CAPR +27.02 pp
EYPT: -97.6% · CAPR: -70.58%
1Y Horizon CAPR +144.21 pp
EYPT: -97.42% · CAPR: +46.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EYPT Revenue CAPR Revenue EYPT Op. Margin CAPR Op. Margin Margin Leader
FY2018 $0M $0M -853.6% -917.0% EYPT
FY2019 $20M $0M -235.0% -769.5% EYPT
FY2020 $30M $0M -108.3% -4412.6% EYPT
FY2021 $40M $0M -149.6% -8549.9% EYPT
FY2022 $40M $0M -240.6% -1163.9% EYPT
FY2023 $50M $30M -163.1% -95.6% CAPR
FY2024 $40M $20M -337.1% -191.1% CAPR
FY2025 $30M N/A -776.0% N/A EYPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EYPT BREAKDOWN
89d in phase · OBV NEUTRAL
Current IV 241.0%
IV Percentile 47th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EYPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EYPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $26.8M market capitalization and -11369.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EYPT vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over EyePoint Pharmaceuticals, Inc. (EYPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). EYPT carries a Unified Composite Score of 43.5/100 (HOLD) at $0.30 (6.2x Forward P/E, -11369.3% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EYPT currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -11369.3% operating margin) and revenue trajectory (-7.9% vs. -90.5% YoY). Technical & Structure Timing Caution: EYPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 17.6); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAPR leads the Growth & Scale pillar: EYPT posts -90.5% YoY revenue growth and +0.0% YoY earnings growth on $2.8M TTM revenue (N/A gross margin, -11369.3% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EYPT cumulative revenue shifted +50.0% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, EYPT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

EYPT screens cheaper on headline valuation multiples. EYPT trades at 6.2x Forward P/E, 6.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EYPT (-148.7% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, EYPT carries 241.0% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.43β · 104% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.